Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|January 1, 1990
Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancerC Lewis, N Lawson, E M Rankin, et al.Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1996
IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancerA C Ogilvie, C E Hack, J Wagstaff, et al.British Journal of Cancer|November 1, 1993
Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumoursM W Dercksen, K Hoekman, W W ten Bokkel Huinink, et al.British Journal of Cancer|February 1, 1992
A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancerE M Rankin, L Mill, S B Kaye, et al.Cancer Research|December 15, 1987
Phase I and pharmacokinetic study of flavone acetic acidD J Kerr, S B Kaye, J Cassidy, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1995
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19L T Vlasveld, A Hekman, F A Vyth-Dreese, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1991
Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trialT Habeshaw, J Paul, R Jones, et al.Hematological Oncology|January 1, 1990
The myelotoxicity of carboplatin is influenced by the time of its administrationD J Kerr, C Lewis, B O'Neil, et al.British Journal of Cancer|May 1, 1992
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspectsL T Vlasveld, E M Rankin, A Hekman, et al.Cancer Chemotherapy and Pharmacology|January 1, 1986
A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervixR E Coleman, P G Harper, C Gallagher, et al.Pageof 5